Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III trial of cotadutide in non-cirrhotic NASH with fibrosis
2021-005484-53Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Cotadutide with Placebo (2 arms). Primary endpoint: Primary endpoints Part A. Started Mar 2022; status: completed.
02
Drugs
cotadutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2021-005484-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005484-53.